Melanoma
News and reporting on melanoma.
Lifileucel's BLA is again delayed, but a 33-month update from a pivotal melanoma trial, along with early data from a frontline study, show continued potential.
The Phase III trial evaluated tebentafusp in patients with HLA-A*02:01-positive metastatic uveal melanoma compared to Keytruda, Yervoy, or chemo.
Nouscom to Evaluate Bespoke Cancer Vaccine NOUS-PEV in European Phase I Study
The personalized neoantigen-based vaccine, manufactured on a per-patient basis, will be evaluated in combination with Keytruda for melanoma and NSCLC. Â
Immunocore to Submit BLA for Tebentafusp in Uveal Melanoma This Year
The FDA also granted tebentafusp breakthrough therapy designation to treat patients with metastatic uveal melanoma.
Circulating Tumor DNA Provides Prognostic Clues in Advanced BRAF-Mutated Melanoma Cases
Using the BRAF-V600 tumor mutation as a marker, investigators identified pre-treatment and on-treatment ties between ctDNA and patient outcomes.